

GLAXOSMITHKLINE PLC  
Form 6-K  
July 20, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 19 July 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- |                                       |                                   |
|---------------------------------------|-----------------------------------|
| a) Name                               | Mr S A Hussain                    |
| b) Position/status                    | President, Global Pharmaceuticals |
| c) Initial notification/<br>amendment | Initial notification              |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |  |
|--|--|
| a) Description of the financial instrument ('Ordinary Shares') | Ordinary shares of 25 pence each<br>ISIN: GB0009252882<br>Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
| b) Nature of the transaction                                   | Price(s) Volume(s)<br>£16.285 109.779 (personal contribution)<br>£16.285 161.359 (personal contribution)<br>£16.285 190.746 (personal contribution)  |
| c) Price(s) and volume(s)                                      | £16.285 190.746 (personal contribution)<br>£16.285 109.779 (matching shares)<br>£16.285 161.359 (matching shares)<br>£16.285 190.746 (matching shares)<br>£16.285 190.746 (matching shares)  |

Aggregated information

- |                             |            |
|-----------------------------|------------|
| d) Aggregated volume        | 1,305.26   |
| Price                       | £16.285    |
| e) Date of the transaction  | 2016-07-14 |
| f) Place of the transaction | n/a        |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: July 19, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc